Several vaccine strategies based on viral vectors have been evaluated in preclinical and clinical trials, with largely disappointing results.
To date the most effective means of GT is based on viral vectors; a tool commonly used by molecular biologists to deliver genetic material into cells [2].
In the last two decades, transgenic system based on viral vectors held promises for gene delivery for the efficient delivery and long-term expression of transgenes to target cells [2].
To overcome this problem, strategies based on viral vector-mediated transfer of miRNA sequences targeting the AAT gene have been developed (Mueller et al, 2012).
Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to improve nucleic acid delivery.
The furthest developed of these vaccines are based on viral vectors, since earlier attempts using inactivated vaccines were unsuccessful, and live-attenuated vaccines are generally considered too dangerous in the case of ebolaviruses.
Since mOSM-RFP is encoded by a single gene it offers numerous possibilities for specific cytokine inhibition in gene delivery approaches based on viral vectors, transgenic animals and finally gene therapy.
Bicistronic expression vectors, based on viral 2A peptides, were generated as follows: pEF-GFP-T2A-delSTOP was made by annealing the T2A primer set, and cloning the double stranded oligo into the EcoRI and BglII sites of pEF-GFPdelSTOP.
Although current strategies on clinical gene therapy are based predominantly on viral vectors, nonviral transfection reagents provide safer alternatives without potential side effects such as immunogenicity and carcinogenesis that are associated with viral transfection [43].
To gain insights into protein expression, we have to transfect cells with kinds of expression vectors, based on plasmid, viral vector, or transposon, etc.
